Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NovAliX Enters into Alliance with Kyowa Hakko Kirin

Published: Monday, January 14, 2013
Last Updated: Monday, January 14, 2013
Bookmark and Share
Companies will collaborate to develop novel drug candidates against protein-protein interaction targets.

NovAliX SAS has announced that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan.

Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets.

NovAliX will generate novel lead candidates using the broad spectrum of its biophysical capabilities and its medicinal chemistry expertise.

Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.

Stephan Jenn, President of NovAliX, stated, "For NovAliX this drug discovery alliance represents a significant development of our established relation with Kyowa Hakko Kirin. This drug discovery collaboration with a leading Japanese pharmaceutical company also confirms the quality of our discovery platforms and its ability to deliver valuable lead candidates."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NovAliX/Kyowa Hakko Kirin Alliance Commence Fragment-Based Drug Discovery Project
The companies will commence research against a new clinically significant target involving the discovery of novel small molecules that modulate protein-protein interaction.
Monday, November 18, 2013
NovAliX and Inventiva Form a Strategic Alliance on Nuclear Receptors
Inventiva and NovAliX announced that they have entered into a strategic alliance dedicated to the discovery of clinical candidates, targeting nuclear receptors.
Tuesday, April 09, 2013
NovAliX Partners with Kyowa Hakko Kirin
NovAliX SAS announced today that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan.
Thursday, January 17, 2013
NovAliX Appoints CSO
Appointment of Dr Luc Van Hijfte as CSO drug discovery.
Wednesday, October 17, 2012
NovAliX and Servier Collaborate in Early Discovery Research Program
Under the terms of Graffinity agreement, a NovAliX subsidiary, will be responsible for the discovery of specific small molecule lead candidates for a novel exploratory target chosen by Servier.
Wednesday, October 10, 2012
NovAliX Enters into Multi-Target Integrated Drug Discovery Collaboration with Teijin Pharma
The companies will develop novel drug candidates against multiple targets across different therapeutic areas.
Thursday, January 12, 2012
NovAliX to Collaborate with the Fondation Jérôme Lejeune on Down Syndrome (Trisomy 21)
NovAliX will use its expertise and capabilities in medicinal chemistry and structural biology to develop small molecule lead candidates targeting the CBS.
Friday, September 16, 2011
NovAliX and Galapagos Collaborate in Osteoarthritis Discovery Research Program
NovAliX will be responsible for the discovery of specific small molecule lead candidates for a novel, validated osteoarthritis target chosen by Galapagos.
Monday, August 29, 2011
Scientific News
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Genetic Cause of Rare Allergy
Institute has identified a genetic mutation responsible for a rare form of inherited hives induced by vibratory urticaria.
Battery Component Found to Harm Key Soil Microorganism
The material at the heart of the lithium ion batteries that power electric vehicles, laptop computers and smartphones has been shown to impair a key soil bacterium, according to new research.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Mitochondria Shown to Trigger Cell Ageing
An international team of scientists has for the first time shown that mitochondria, the batteries of the cells, are essential for ageing.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Validating the Accuracy of CRISPR-Cas9
IBS Researchers create multiplex Digenome-seq to find errors in CRISPR-Cas9 processes.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!